Form 4: Vaxcyte CFO Andrew Guggenhime Reports Stock Option Exercise and Share Sales
SEC Form 4 Filing
Andrew Guggenhime, President and CFO of Vaxcyte, Inc., exercised stock options and sold shares of common stock on May 20, 2024, according to a Form 4 filing with the SEC.
Summary
- On May 20, 2024, Andrew Guggenhime, the President and CFO of Vaxcyte, Inc., exercised stock options to acquire 8,000 shares of common stock at a price of $5.35 per share.
- He then sold 3,544 shares at a weighted average price of $74.396, with prices ranging from $73.95 to $74.90.
- Additionally, he sold 4,456 shares at a weighted average price of $75.46, with prices ranging from $74.95 to $75.88.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 30, 2023.
- Following these transactions, Guggenhime directly owns 95,679 shares of Vaxcyte common stock and 352,827 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This filing reflects routine insider trading activity, which is common in publicly traded companies. Insiders often use Rule 10b5-1 trading plans to avoid accusations of trading on non-public information.
Comparison to Industry Standards
- Executive compensation packages often include stock options to align management's interests with those of shareholders.
- Rule 10b5-1 trading plans are a standard practice among corporate executives to manage their stock holdings and avoid insider trading concerns.
- The reported transactions are typical for executives holding significant equity in their companies.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal given the relatively small number of shares involved.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 05/01/2021 | 1/4 of the shares subject to the option vested. |
| 06/30/2023 | Rule 10b5-1 trading plan adopted. |
| 05/20/2024 | Date of stock option exercise and share sales. |
| 05/22/2024 | Date of signature on the Form 4 filing. |
| 05/11/2030 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.